Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 2/20 | 0.38 |
| ▸ | PKM | P14618 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.36 |
| ▸ | HPGD | P15428 | 2/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | PIK3CD | O00329 | 1/20 | 0.35 |
| ▸ | PIK3CA | P42336 | 1/20 | 0.35 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.35 |
| ▸ | PI4KA | P42356 | 1/20 | 0.35 |
| ▸ | PI4KB | Q9UBF8 | 1/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.33 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.33 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.33 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14616991 | 0.81 | NPC1 (0.31) | NPC1 | |
| SCHEMBL25088030 | 0.80 | PKM (0.39) | PKMKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL11355247 | 0.78 | PKM (0.38) | PKMKDM4EALDH1A1HPGDTDP1 | |
| SCHEMBL11514300 | 0.78 | ALDH1A1 (0.46) | PKMKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL5748988 | 0.78 | HRH3 (0.46) | PIK3CAHRH3 | |
| SCHEMBL15912734 | 0.77 | HSP90AB1 (0.51) | KDM4EALDH1A1SMN1; SMN2TDP1POLB | |
| SCHEMBL22853068 | 0.77 | KDM4E (0.37) | PKMKDM4EALDH1A1HPGDSMN1; SMN2 | |
| SCHEMBL10617676 | 0.77 | ALDH1A1 (0.46) | NPC1PKMKDM4EALDH1A1HPGD | |
| SCHEMBL13153625 | 0.74 | NOS2 (0.48) | KDM4EALDH1A1SMN1; SMN2HSD17B10LMNA | |
| SCHEMBL30227466 | 0.74 | NOS2 (0.48) | KDM4EALDH1A1SMN1; SMN2HSD17B10LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4744661-A2 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2026-05-20 | — | — | EP | disclosed |
| EP-4298092-B1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN LA ROCHE (CH) | 2025-11-26 | — | — | EP | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. (US) | 2024-01-25 | — | — | US | disclosed |
| EP-4298092-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. Hoffmann-La Roche AG (CH) | 2024-01-03 | — | — | EP | disclosed |
| CN-116829550-A | Pyrimidine-2-ylsulfonamide derivatives | 豪夫迈·罗氏有限公司 | 2023-09-29 | — | — | CN | disclosed |
| WO-2022180136-A1 | NOVEL PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2022-09-01 | — | — | WO | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-7488721-B2 | Real time methylumbelliferone-based assay | MCMASTER UNIVERSITY (CA) | 2009-02-10 | — | — | US | disclosed |
| US-20060008862-A1 | Real time methylumbelliferone-based assay | THE HOSPITAL FOR SICK CHILDREN | 2006-01-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240025883-A1 | PYRIMIDIN-2-YL SULFONAMIDE DERIVATIVES | GPR17, GPR27, GPR119 | NPC1 424/4885PKM 2531/4885KDM4E 3786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.